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cells) in 7 TET WHO C (70%, including the paired primary/second-
ary tumor), a mild expression (1+ positivity on 100% of the cell) was 
observed in 2 TET WHO C, 1 TET WHO C was c-kit negative, all the 
A, AB, B1-3 WHO subtypes were negative. A nuclear HER2 staining 
was observed for 1 TET WHO A, 2 TET WHO AB, 3 TET WHO B2, 2 
TET WHO B3, and 1 micronodular TET. The 2 carcinoid tumors were 
strongly positive for c-kit and negative for CD20 and HER2.
Conclusions: CD20 and c-kit expression are restricted to TET WHO 
AB and C respectively. HER2 nuclear staining pattern is of unknown 
signiﬁcance. VEGFR 1-2 data will be presented at the meeting.
P2-039 BSTB: Molecular Targets Posters, Tue, Sept 4 
Mechanisms controlling survival and induction of apoptosis 
following 12-lipoxygenase (LOX) inhibition in non small cell lung 
cancer (NSCLC)
Campbell, Vikki1 Lysaght, Joanne1 Gately, Kathy2 Kay, Elaine3 
Reynolds, John2 Pidgeon, Graham P.1 O’Byrne, Kenneth J.2 
1 Trinity College, Dublin, Ireland 2 St. James Hospital, Dublin, Ireland 3 
Royal College of Surgeons Ireland, Dublin, Ireland 
Background: Platelet-type 12-Lipoxygenase is an arachidonic acid 
metabolising enzyme that results in the formation of 12(S)-HETE. 
12(S)-HETE is proangiogenic, and has been shown to stimulate tumour 
cell adhesion, invasion and metastasis. Inhibitors of 12-LOX are cur-
rently undergoing extensive investigation, and a detailed examination of 
the effects of these agents in lung cancer is warranted. In this study we 
examined the expression proﬁle of 12-LOX in human lung cancer cell 
lines and resected tissue. We also examined the mechanisms responsible 
for apoptosis following selective inhibition of 12-LOX with baicalein. 
Methods: A549 (adenocarcinoma), SK-MES1 (squamous cell lung 
carcinoma), H460 and H647 (large cell lung carcinoma) were grown 
in serum depleted media (0.5%) and screened for 12-LOX expression 
by RT-PCR and western blot analysis. Cells were treated with baicalein 
(10uM), a selective inhibitor of 12-LOX, or 12(S)-HETE (100ng/ml) 
and cell survival / proliferation determined by BrdU assay. Apoptosis 
was determined using the multi-parameter apoptosis kit and In-cell 
Analyser, DNA laddering and also by FACS. Gene alterations follow-
ing 12-LOX inhibition in both A549 and SKMES-1 cells were assessed 
by quantitative PCR arrays and validated by RT-PCR. A panel of retro-
spective resected lung tumours were stained for 12-LOX expression by 
immunhistochemistry. 
Results: All lung cancer cells lines expressed moderate levels of plate-
let-type 12-LOX, which was reduced following treatment for 24h with 
increasing concentrations of baicalein. Baicalein decreased lung cancer 
survival in all cell lines, while 12(S)-HETE increased cellular prolif-
eration. Inhibition of 12-LOX induced apoptosis in a dose dependent 
manner, with decreased f-actin ﬁlaments and loss of mitochondrial 
mass potential. Induction of apoptosis was also conﬁrmed by DNA 
laddering and Annexin-V FACS labelling. QPCR array data implicated 
a number of genes regulating these effects which were validated by RT-
PCR, many of which control apoptosis and angiogenesis. The subset 
of genes downregulated included bcl-2, VEGF, integrin α2 and α4. 
12-LOX expression was observed in a variety of human lung cancers 
with different histological subtypes. We are currently silencing 12-LOX 
expression in these cells, using shRNA technology, to further examine 
these mechanisms.
Conclusions: 12-LOX is a survival factor in NSCLC. 12-LOX inhibi-
tion decreased NSCLC survival, inducing apoptosis through mecha-
nisms including downregulation of the bcl family of proteins, integrin 
receptor and angiogenic growth factors. Expression of 12-LOX in fresh 
resected and retrospective tissue suggests that inhibition of this enzyme 
is a potential therapeutic strategy in the treatment of NSCLC.
P2-041 BSTB: Molecular Targets Posters, Tue, Sept 4 
Epigenetic changes of the tumor suppressor genes SHP1, SHP2 
SOCS1, SOCS3 and the transcription factor STAT1 in human lung 
cancer
Gullbo, Joachim1 Bergqvist, Michael1 Sooman, Linda1 Ericsson, Peter1 
Lennartsson, Johan2 Brattström, Daniel3 Bergström, Stefan1 Ekman, 
Simon1 
1 ORKI, Uppsala, Sweden 2 Ludwig Institute for Cancer Research, Up-
psala, Sweden 3 Karolinska University Hospital, Stockholm, Sweden 
Background: Abberant DNA methylation, including hypermethylation 
of tumor suppressor genes or hypomethylation of oncogenes, is a hall-
mark of cancer and can be found in almost all cancer types. Informa-
tion about which methylation events are disease speciﬁc and also have 
effect on gene expression has a great potential in diagnostics and drug 
development. The aim of this study was to investigate the methylation 
status of the tumor suppressor genes SHP1, SHP2, SOCS1 and SOCS3 
and the transcription factor STAT1, and its effect on protein expression 
and tumor biology in lung cancer cell lines. Their activities are required 
for a functional regulation of cell growth and these genes have previ-
ously shown hypermethylation-associated tumor occurrence in several 
other types of cancers.
Methods: To study methylation patterns, bisulﬁte treatment of total 
DNA followed by PCR ampliﬁcation and Pyrosequencing® analysis 
was employed. The gene regions to be analyzed were determined ac-
cording to the regions that previously had shown aberrant methylation 
patterns in other types of cancers and psoriasis. Expression levels of the 
different proteins were evaluated by immunoprecipitation using anti-
bodies directed against each protein, followed by SDS-Polyacrylamide 
Gel Electrophoresis (SDS-PAGE) and Western blotting.
Five NSCLC cell lines and ﬁve SCLC were used in the studies.
Results: The methylation studies showed that the genes SHP1, SOCS1 
and SOCS3 are strongly methylated in some of the analyzed lung 
cancer (LC) cell lines, whereas SHP2 and STAT1 were not signiﬁcantly 
methylated in any cell line. The protein expression studies showed 
that the observed methylation levels in SHP1 were associated with a 
reduction of protein expression in the LC cell lines. Furthermore, the 
promoter region 1 (SHP1 A) of SHP1 demonstrated varying degrees of 
methylation throughout the LC cell lines, whereas promoter region 2 
(SHP1 B and C) was highly methylated in all cell lines. The epigenetic 
regulation of SHP1 has earlier been attributed to promoter region 2. 
In this study, on the other hand, the reduced protein expression seems 
to be associated with methylation in promoter region 1. SHP1 has 
earlier been reported to be methylated in promoter region 2 in normal 
epithelial cells, but to our knowledge there have been no reports on 
methylation in promoter region 1. The importance of the reduced SHP1 
expression in the regulation of proliferation, migration and invasion 
are being analyzed in the lung cancer cell lines and further data will be 
presented at the meeting.
Conclusions: The tumor suppressor genes SHP1, SOCS1 and SOCS3 
are highly methylated in lung cancer cell lines, making them potential 
diagnostic markers for lung cancer. Furthermore, methylation of the 
SHP1 promoter region 1 is associated with a strongly reduced protein 
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expression of SHP1, indicating a possible role in the tumor formation 
in lung cancer and pointing to novel therapeutic strategies.
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Background: Tumor-associated extracellular matrix molecules are 
isoforms of proteins with a wide distribution in normal adult tissues, 
such as ﬁbronectin and tenascin. Large Tenascin-C isoforms are present 
in almost all normal adult tissues but are upregulated in fetal, regenerat-
ing, and neoplastic tissues. In this study we investigated the expression 
of three tenascin isoforms in tumor tissue samples from lung cancer 
patients to evaluate the diagnostic and therapeutic value for clinical 
applications.
Methods: In total, 35 corresponding tissue samples (tumor and normal 
lung tissue of the same patient) have been analyzed by immunohis-
tochemistry using three different human monoclonal antibodies to 
domains A1 (F16), C (G11) and D (P12). All tumor specimens have 
been non-small cell lung cancer types.
Results: Three isoforms G11, F16 and P12 have exhibited a very 
intense staining of different histological types of lung cancer. More 
than 80% of squamous cell carcinomas, adenocarcinomas and large cell 
carcinoma samples have been positively stained. None of the corre-
sponding normal lung tissue specimens showed an expression of either 
tenascin domains.
Conclusions: The results show that tenascin-C isoforms are highly 
expressed around the neovasculature and in the stroma of the majority 
of non-small cell lung cancers but is undetectable in the normal lung 
tissue. Therefore these isoforms could represent valuable candidates for 
the development of antibody based biopharmaceuticals for the treat-
ment of lung cancer.
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The Eph proteins compromise a family of receptor tyrosine kinases that 
are involved in cell-cell interactions, morphogenesis and angiogenesis. 
Especially, EphA2 receptor has been implicated in neovascularization 
of various cancers with its ligand, ephrin A1. How interaction between 
EphA2 and ephrin A1 was concerned with intracellular signaling 
pathway remains to be controversial. As for cancer, other investigations 
has demonstrated that EphA2 is regulated by p53-family proteins, E-
cadherin and ras gene. Especially, in recent reports EphA2 in non-small 
lung cancer may provide a promising marker to predict patients with 
brain metastasis.
Purpose: The purpose of this study is to determine whether EphA2 
correlates with tumor progression, angiogenesis, p53 and E-cadherin 
mediated adhesion in non-small lung cancer. 
Experimental Design: We evaluated EphA2 and ephrin A1 us-
ing immunohistochemistry in 41 cases (I:14, III:27) with long-term 
follow up. Additionally the relationship among EphA2 expression, 
MVD(microvascular density), clinicopathological parameters, and E-
cadherin expression was assessed. 
Results: EphA2 expression was identiﬁed in 28 cases(68.3%). Stage I 
cases displayed signiﬁcantly lower levels than stage III cases(p=0.017). 
Survival curve determined by the Kaplan Meier method demonstrated 
that strong immunoreactivity for EphA2 was associated with overall 
survival (p=0.028). The MVD in EphA2 positve group was signiﬁcant-
ly higher than that in EphA2 negative group (p=0.006). In imuunohis-
tochemical study EphA2 expression was related to loss of E-cadherin 
(p=0.041), but not to p53 on serial sections.
Conclusions: EphA2 expression was associated with tumor progres-
sion, angiogenesis and loss of E-cadherin. 
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Somatic mutations in epidermal growth factor receptor (EGFR) 
tyrosine kinase domain predicts the response to EGFR tyrosine kinase 
inhibitor (TKI) in non-small cell lung cancer (NSCLC). The emergence 
of acquired resistance to EGFR TKI has been recently described in 
patients whose tumor initially responded to geﬁtinib. Lapatinib is a 
dual inhibitor of ErbB1 (EGFR) and ErbB2 (HER-2) tyrosine kinases 
and has shown promising efﬁcacy in HER-2 overexpressing breast 
cancer. However, its therapeutic role is not fully studied in NSCLC. 
Here we report that lapatinib enhances cytotoxicity against geﬁtinib-
resistant NSCLC by blocking active heterodimerization of EGFR and 
HER-2. We identiﬁed a secondary T790M mutation in a NSCLC tumor 
with a geﬁtinib-sensitive L858R mutation that eventually progressed 
after initial response. Acquired T790M mutation conferred resistance 
to L858R mutant cells sensitive to geﬁtinib. Of the various molecules 
downstream of EGFR, signal transduction and activator of transcription 
3 (Stat3) signaling was continuously activated in L858R/T790M cells, 
and the inhibition of Stat3 suppressed geﬁtinib-resistant cell growth. 
As for Stat3 inhibition, we found that lapatinib inactivated Stat3 and 
inhibited cell growth in geﬁtinib-resistant NSCLC. Finally, lapatinib 
was also found to block the heterodimerization of EGFR and HER-2, 
and this led to the inactivation of Stat3 in geﬁtinib-resistant T790M 
cells, whereas the active heterodimerization of EGFR and HER-2 was 
maintained when these cells were treated with geﬁtinib. Taken together, 
our data suggest that lapatinib may overcome geﬁtinib resistance in 
NSCLC. A clinical investigation of the use of lapatinib in geﬁtinib-re-
sistant NSCLC is strongly warranted.
